Immunoadsorption of factor VIII inhibitors

Current Opinion in Hematology

Volumn 11, Issue 5, 2004, Pages 327-333

  Freedman, John ^a,b   Garvey, M Bernadette ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b 2 Cardinal Carter Wing ^*  (Canada)

Author keywords

Hemophilia; Immunoadsorption; Inhibitors; Protein A

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; ESTER DERIVATIVE; POLYSTYRENE; SULFONIC ACID DERIVATIVE; TYROSINE DERIVATIVE;

BLEEDING; COST EFFECTIVENESS ANALYSIS; HEMOPHILIA; HUMAN; IMMUNOADSORBENT; IMMUNOADSORPTION; IMMUNOLOGICAL TOLERANCE; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNOSORBENT TECHNIQUES; IMMUNOSORBENTS; ISOANTIBODIES;

EID: 13544277095     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.moh.0000139998.68132.d2     Document Type: Review

References (78)

1. Hoyer LW, Gawryl MS, de la Fuente B: Immunochemical characterization of factor VIII inhibitors. Prog Clin Biol Res 1984, 150:73-85.
2. Fulcher CA, de Graaf Mahoney S, Zimmerman TS, et al.: FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987, 69:1475-1480.
3. Gawryl MS, Hoyer LW: Inactivation of factor VIII coagulant activity by two different types of antibodies. Blood 1982, 60:1103-1109.
4. Saenko EL, Ananyeva NM, Kouiavskala DV, et al.: Haemophilia A: effect of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action. Haemophilia 2002, 8:1-11.
5. Gjorstrup P, Berntorp E, Larsson L, et al.: Kinetic aspect of the removal of IgG and inhibitors in hemophiliacs using protein A. Vox Sang 1991, 61:244-250.
6. Nilsson IM, Freiburghaus C: Apheresis. Adv Exp Med Biol 1995, 386:175-184.
7. Aledort LM: Unsolved problems in haemophilia. Haemophilia 1998, 4:341-345.
8. Huestis DW, Morrison FS: Adverse clinical effects of immune sorption with staphylococcal protein A columns. Transfus Med Rev 1996, 10:62-70.
9. Siami GA, Siami FS: The current status of therapeutic apheresis devices in the United States. Int J Artif Organs 2002, 25:499-502.
10. Vamvakas CE, Pineda AA: Selective extraction of plasma components. In: McLeod BC, Price TH, Drew MJ, editors. Apheresis: principles and practice. Bethesda, MD: AABB Press; 1997, 375-407.
11. Matic G, Bosch T, Ramlow W: Background and indications for protein A-based extracorporeal immunoadsorption. Ther Apher 2001, 5:394-403.
12. Freedman J, Semple JW, Teitel J, et al.: Clinical and immunologic effects of staphylococcal protein A immunoadsorption therapy for inhibitor to factor VIII. Transfus Sci 1992, 13:223-232.
13. Braun N, Risler T: Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease. Ther Apher 1999, 3:240-245.
14. Graille M, Stura EA, Corper AL, et al.: Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. Proc Natl Acad Sci USA 2000, 97:5399-5404.
15. Alonso DO, Daggett V: Staphylococcal protein A: unfolding pathways, unfolded states, and differences between the B and E domains. Proc Natl Acad Sci USA 2000, 97:133-138.
16. Ljungberg UK, Jansson B, Niss U, et al.: The interaction between different domains of Staphylococcal protein A and human polyclonal IgG, IgA, IgM and F(ab′)2: separation of affinity from specificity. Mol Immunol 1993, 30:1279-1285.
17. Potter KN, Li Y, Mageed RA, et al.: Anti-idiotypic antibody D12 and superantigen SPA both interact with human VH3-encoded antibodies on the external face of the heavy chain involving FR1, CDR2 and FR3. Mol Immunol 1998, 35:1179-1187.
18. Silverman GJ, Cary SP, Dwyer DC, et al.: A B-cell superantigen-induced persistent "Hole" in the B-1 repertoire. J Exp Med 2000, 192:87-98.
19. Kozlowski LM, Li W, Goldschmidt M, et al.: In vivo inflammatory response to a prototypic B cell superantigen: elucidation of an Arthus reaction by staphylococcal protein A. J Immunol 1998, 160:5246-5252.
20. Sinha P, Ghosh AK, Das T, et al.: Protein A of Staphylococcus aureus evokes Th 1 type response in mice. Immunol Lett 1999, 67:157-165.
21. Schneidewind-Muller J-M, Winkler RE, Tiess M, et al.: Changes in lymphocytic cluster distribution during extracorporeal immunoadsorption. Artif Organs 2002, 26:140-144.
22. Jansen M, Schmaldienst S, Banyai S, et al.: Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 2001, 112:91-97.
23. Taleghani BM, Grossmann R: Treatment of patients with factor VIII autoantibodies by staphylococcal protein A-based immunoadsorption and immunosuppression. Br J Haematol 2001, 114:956-957.
24. Guillet B, Kriaa F, Huysse MG, et al.: Protein A sepharose immunoadsorption: immunological and haemostatic effects in two cases of acquired haemophilia. Br J Haematol 2001, 114:837-844.
25. Nilsson IM, Jonsson S, Sundqvist SB, et al.: A procedure for removing high titer antibodies by extracorporeal protein-A-Sepharose adsorption in hemophilia: substitution therapy and surgery in a patient with hemophilia B and antibodies. Blood 1981, 58:38-44.
26. Freiburghaus C, Berntorp E, Ekman M, et al.: Immunoadsorption for removal of inhibitors: update on treatments in Malmo-Lund between 1980 and 1995. Haemophilia 1998, 4:16-20.
27. Nilsson IM, Sundqvist SB, Freiburghaus C: Extracorporeal protein A-Sepharose and specific affinity chromatography for removal of antibodies. Prog Clin Biol Res 1984, 150:225-241.
28. Watt R, Bunitsky K, Faulkner E, et al.: Treatment of congenital and acquired hemophilia patients by extracorporeal removal of antibodies to coagulation factors: a review of US clinical studies 1987-90. Transfus Sci 1992, 13:233-253.
29. Gjörstrup P, Watt RM: Therapeutic protein A immunoadsorption: a review. Transfus Sci 1990, 11:281-302.
30. Kriaa F, Laurian Y, Hiesse C, et al.: Five years experience at one centre with protein A immunoadsorption in patients with deleterious allo/autoantibodies (anti-HLA antibodies, autoimmune bleeding disorders) and post-transplant patients relapsing with focal glomerular sclerosis. Nephrol Dial Transplant 1995, 10:108-110.
31. Nilsson IM, Berntorp E, Zetterval O: Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988, 318:947-950.
32. Taleghani BM, Grossman R, Keller F, et al.: Therapy of coagulation factor VIII autoantibodies with long-term extracorporeal protein A adsorption and immunosuppression. Transfus Sci 1998, 19(Suppl):39-42.
33. Knöbl P, Derfler K, Korninger I, et al.: Elimination of acquired factor VIII antibodies by extracorporeal antibody-based immunoadsorption (Ig-Therasorb). Thromb Haemost 1995, 74:1035-1038.
34. Knöbl P, Derfler K: Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX. Vox Sang 1999, 77(Suppl 1):57-64.
35. Toepfer M, Rommel F, Sitter T, et al.: Reduction of acquired high titer factor VIII antibodies by extracorporeal antibody-based immunoadsorption without additional immunosuppressive therapy. Thromb Haemost 1998, 80:1035-1036.
36. Rivard GE: Use of protein-A column and porcine factor VIII. Haemophilia 2002, 8(Suppl. 1):20-23.
37. Astermark J: Treatment of the bleeding inhibitor patient. Semin Thromb Hemost 2003, 29:77-85.
38. Rivard GE, St Louis J, Lacroix S, et al.: Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution. Haemophilia 2003, 9:711-716. Reviews the experience with 10 patients over 3 years, suggesting that this approach may be more useful in acquired hemophilia than in severe congenital factor deficiencies with inhibitors.
39. Freedman J, Rand M, Russell O, et al.: Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIII. Transfusion 2003, 43:1508-1513. Case reports indicating rapid and lasting effect in patients with acquired hemophilia and severe clinical manifestations; provides cost data of therapies before, during, and after immunoadsorption, suggesting marked cost benefit to early institution of immunoadsorption in appropriate patients.
40. Linden JV, Kolakoski MH, Lima JE, et al.: Factor concentrate usage in persons with hemophilia in New York State. Transfusion 2003, 43:470-475.
41. Wight J, Richards M: Very high cost treatment for a single individual - a case report. J Public Health Med 2003, 25:4-7.
42. Aledort LM: Economics of hemophilia care. Haemostasis 2001, 30:333-336.
43. Mariani G, Kroner B: Immune tolerance in hemophilia and inhibitors: a cost analysis. Transfusion 2000, 40:495-496.
44. Bohn RL, Aledort LM, Putnam KG, et al.: The economic impact of factor VIII inhibitors in patients with hemophilia. Haemophilia 2004, 10:63-68. This retrospective cohort study examined product use in hemophilia. The median cost was 20-fold higher for patients with inhibitors than those without, and "outlier" patients accounted for a large percentage of the costs of care. The authors emphasize that treatment choices must take costs into account.
45. Hadden RDM, Bensa S, Lunn MPT, et al.: Immunoadsorption inferior to plasma exchange in a patient with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2002, 72:644-646.
46. Leitner GC, Stiegler G, Horvath M, et al.: Idiopathic autoimmune thrombocytopenia: evidence for redistribution of platelet antibodies into the circulation after immunoadsorption treatment. Am J Hematol 2003, 73:44-47.
47. Boisson-Vidal C, Haouam M, Lakhiari H, et al.: Polystyrene derivatives as candidates for extracorporeal adsorption of factor VIII antibodies in the management of haemophiliac patients. Vox Sang 2002, 83:214-221.
48. Huguet H-C, Lasne D, Rothschild C, et al.: Extracorporeal adsorption of anti-factor VIII allo-antibodies on randomly functionalized polystyrene resins. Thromb Haemost 2004, 91:259-266. This novel and intriguing work describes synthetic resins capable of removing anti-FVIII antibodies efficiently, avoiding the potential adverse effects of SPA and reduction in other immunoglobulins, including IgG. This may represent a major technological advance in selective removal of FVIII inhibitors.
49. Zeuner RA, Beress R, Schroeder JO, et al.: Effect of antigen-specific immunoadsorption on antibody kinetics in a rat model. Biomater Artif Cells Immobilization Biotechnol 1993, 21:199-211.
50. Borberg H, Jiminez C, Belák M, et al.: Treatment of autoimmune disease by immunomodulation through extracorporeal elimination and intravenous immunoglobulin. Transfus Sci 1994, 4:409-418.
51. Matic G, Hofmann D, Winkler R, et al.: Removal of immunoglobulins by a protein A versus an antihuman immunoglobulin G-based system: evaluation of 602 sessions of extracorporeal immunoadsorption. Artif Organs 2000, 24:103-107.
52. Ptak J: Changes of plasma proteins after immunoadsorption using Ig-adsopak columns in patients with myasthenia gravis. Transfus Apheresis Sci 2004, 30:125-129.
53. Von Depka Prondzinski M: Erworbene hämophilie infolge antikörperbildung gegen Faktor VIII. Hamostaseologie 2003, 23:28-35.
54. Rommel F, Toepfer M, Eberle J, et al.: Reactivation of chronic hepatitis C virus infection by immunoadsorption in factor VIII inhibitor haemophilia. Thromb Haemost 2000, 84:733-734.
55. Böhm M, Dörner T, Knebel F, et al.: Longlasting effects of immunoadsorption in severe Sjogren's syndrome. Ann Rheum Dis 2004, 63:214-215.
56. Collins PW: Management of acquired haemophilia A: more questions than answers. Blood Coagul Fibrinolysis 2003, 14(suppl 1):S23-S27.
57. Sultan Y, Kazatchkine MD, Nydegger U, et al.: Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII:C inhibitors. Am J Med 1991, 91:S35-S39.
58. Schwartz RS, Gabriel DA, Aledort LM, et al.: A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood 1995, 86:797-804.
59. Dittrich E, Schmaldienst S, Langer M, et al.: Immunoadsorption and plasma exchange in pregnancy. Kidney Blood Press Res 2002, 25:232-239.
60. Rabitsch W, Knöbl P, Greinix H, et al.: Removal of persisting isohaemagglutinins with Ig-Therasorb® immunoadsorption after major ABO-incompatible non-myeloablative allogeneic haematopoietic stem cell transplantation. Nephrol Dial Transplant 2003, 18:2405-2408.
61. Rabitsch W, Knöbl P, Prinz E, et al.: Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb® immunoadsorption. Bone Marrow Transplant 2003, 32:1015-1019.
62. Ritter MM, Parhofer KG: Extracorporal low-density lipoprotein elimination by immunoadsorption. Ther Apher Dial 2003, 7:370-372.
63. Kramer L, Bauer E, Jansen M, et al.: Mercury exposure in protein A immunoadsorption. Nephrol Dial Transplant 2004, 19:451-456.
64. Lüftl M, Stauber A, Mainka A, et al.: Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinyl alcohol adsorber. Br J Dermatol 2003, 149:598-605.
65. Staudt A, Böhm M, Knebel F, et al.: Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation 2002, 106:2448-2453.
66. 1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. J Autoimmun 2003, 20:345-350.
67. Rönspeck W, Brinckmann R, Egner R, et al.: Peptide based adsorbers for therapeutic immunoadsorption. Ther Apher Dial 2003, 7:91-97.
68. Andersen SM, Ling C-C, Zhang P, et al.: Synthesis of ganglioside epitopes for oligosaccharide specific immunoadsorption therapy of Guillian-Barre syndrome. Org Biomol Chem 2004, 2:1199-1212.
69. 2-m, the approach may have potential for other disorders, including antibodies to FVIII.
70. Takeshima K, Smith C, Tait J, et al.: The preparation and phospholipid binding property of the C2 domain of human factor VIII. Thromb Haemost 2003, 89:788-794.
71. Lewis DA, Pound ML, Ortel TL: Contributions of Asn2198, Met2199, and Phe2200 in the factor VIII C2 domain to cofactor activity, phospholipid-binding, and von Willebrand factor-binding. Thromb Haemost 2003, 89:795-802.
72. Purohit VS, Ramani K, Kashi RS, et al.: Topology of factor VIII bound to phosphatidylserine-containing model membranes. Biochim Biophys Acta 2003, 1617:31-38.
73. Raut S, Villard S, Grailly S, et al.: Anti-heavy-chain monoclonal antibodies directed to the acidic regions of the factor VIII molecule inhibit the binding of factor VIII to phospholipids and von Willebrand factor. Thromb Haemost 2003, 90:385-397.
74. Lollar P: Molecular characterization of the immune response to factor VIII. Vox Sang 2002, Suppl 1:403-408.
75. d'Oiron R, Lavergne J-M, Lavend'homme R, et al.: Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development. Blood 2004, 103:155-157.
76. Gilles JG, Grailly SC, de Maeyer M, et al.: In vivo neutralization of a C2 domain-specific human anti-factor VIII inhibitor by an anti-idiotypic antibody. Blood 2004, 103:2617-2623.
77. Villard S, Lacroix-Desmazes S, Kieber-Emmons T, et al.: Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor. Blood 2003, 102:949-952. This paper reports a novel approach aimed at neutralizing FVIII inhibitor activity by use of decoy peptide epitope surrogates.
78. Bayri J, Lacroix-Desmazes S, Pashov A, et al.: Autoantibodies to factor VIII with catalytic activity. Autoimmun Rev 2003, 2:30-35. This represents the first example in humans of the induction of catalytic antibodies following the exogenous administration of an antigen. The characterization of FVIII inhibitors as site-specific proteases may provide new approaches to the treatment of inhibitors.